Doebele R, et al. Efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC). IASLC 2018; abstract OA02.01.
Neoadjuvant pertuzumab plus trastuzumab met of zonder chemotherapie: 5-jaarsoverlevingsdata
jun 2022 | Borstkanker